Poor prognosis is associated with oral squamous cell carcinoma (OSCC), an aggressive form of malignant tumor.1 This study aimed to investigate the pharmacological effects of carvacrol on OSCC by targeting the tumor-associated antigen FGFR1. As a key survival biomarker in OSCC, FGFR1 plays a crucial role in malignant transformation. Carvacrol, a specific FGFR1 inhibitor, induces its degradation via the ubiquitin-proteasome pathway.